semaglutide and ovarian cancer GLP-1 RAs linked to broad menstrual adverse event signals in reproductive-aged patients GLP-1 Weight-Loss Meds Linked to

Important Risk Information Material Risks: Tirzepatide is associated with a risk of thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), based on animal studies

The safety profile and side effects of semaglutide have been extensively studied

We cover weight history (when did the trajectory change, what's been tried, what worked and didn't), lifestyle (sleep, activity, eating patterns, stress, medication list), and a focused exam

Data will be made available to the editors of the journal pre- and/or post-publication for review or query upon request

Researchers are now taking a closer look at these other potential indications for GLP-1 agonists